$EBS

Emergent BioSolutions (EBS) announced CFO Richard Lindahl will step down by Dec 31, 2026, and retire by Mar 31, 2027. Frank Vargo, VP of Treasury, will serve as interim CFO starting Jan 1, 2027.

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl • Appointment of Frank Vargo, VP, Treasurer, to Interim CFO effective January 1, 2027 GAITHERSBURG, Md., October 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today anno

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

Novavax (NVAX) shares surged 20% after a suspected plague death in Russia sparked investor interest in vaccine stocks. Moderna (MRNA) rose 7.1% and Emergent BioSolutions (EBS) gained 15.3%. The rally is attributed to short covering and sentiment, not new revenue prospects. NVAX's short interest is 30.43% of its float, setting up a potential squeeze.

Emergent Biosolutions (EBS) stock rose 19.6% to $7.57 after a suspected pneumonic plague death in Russia. The company's biodefense portfolio and strong Q2 earnings, with adjusted EPS of $0.60 and revenue of $234.3M, supported the surge. Analysts have a consensus 'Hold' rating with a $10.00 price target. The broader market also gained, with the S&P 500 up 0.7% and Nasdaq up 1.0%.

Emergent BioSolutions (EBS) received a $24M contract modification from BARDA for its CYFENDUS anthrax vaccine, supporting national preparedness. The FDA-approved vaccine is used for post-exposure prophylaxis. EBS stock is up 0.82% at $6.15.

S&P Global Ratings revised Emergent BioSolutions' outlook to negative, citing lower revenue guidance due to competition in the naloxone market. The company reduced its 2026 revenue and EBITDA guidance by $80M and $25M, respectively, due to weaker NARCAN sales. S&P noted potential refinancing risks for Emergent's $440M unsecured notes maturing in 2028, with declining revenue and uncertain growth prospects.

Emergent BioSolutions (EBS) reported Q2 updates on its MCM and naloxone franchises. Management said MCM international sales were about 20% of first-half 2026 revenue. It received regulators’ approvals to expand ACAM2000 to Mpox. Due to NARCAN competition, EBS lowered 2026 revenue guidance to $645M-$675M and recorded a ~$191M non-cash impairment, plus ~$40M annualized cost savings.

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

Emergent BioSolutions (EBS) reported Q2 2026 revenue of $234.3 million, up 66% year over year, driven by accelerated U.S. government MCM contract modifications. Net loss widened to $180.2 million due to a $191.3 million non-cash Naloxone impairment. Adjusted EBITDA rose to $96.5 million. The company cut 2026 guidance and announced restructuring, including wet lab closures and about 93 job reductions.